Sandoz's Enzeevu receives FDA approval for wet age-related macular degeneration
A significant step for affordable access to biologic medicines
Conclusion
The FDA's approval of Enzeevu marks a significant milestone in the healthcare industry. As a biosimilar that offers comparable efficacy and safety to Eylea at a lower cost, Enzeevu has the potential to revolutionize the treatment of wet AMD and improve outcomes for millions of patients worldwide. Sandoz's commitment to providing affordable and accessible healthcare through biosimilars is a testament to their mission of empowering patients and transforming the future of medicine.
Komentar